Pharma firm Lupin Ltd. has introduced the acquisition of diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH together with the trademark rights related to these brands for €26 million.
Lupin has been advertising these brands since 2015 within the Indian market as a part of a co-marketing settlement with Boehringer Ingelheim India.
“This acquisition strengthens Lupin’s commitment to providing superior treatment options for patients navigating the complexities of diabetes,” the corporate stated in an announcement.
“With the acquisitions, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” stated Nilesh Gupta, Managing Director, Lupin in an announcement.
